By Michael A. Samara, MD. A discussion about the growing population of patients with heart failure, advances in heart failure therapies, and the role of ECMO and LVAD implants in improving outcomes. "ECMO is an older therapy that is undergoing a renaissance. We've learned that poorer outcomes were a consequence of resorting to ECMO too late after multiple system failure. Now we're starting ECMO in the cath lab, even during active CPR."
Call Girls Colaba Mumbai ❤️ 9920874524 👈 Cash on Delivery
Advanced Heart Failure Therapies: Cardiac Transplantation and Mechanical Circulatory Support
1. Michael A. Samara, MD, FACC
AdvancedHeartFailureTherapies
Cardiac Transplantation and Mechanical Circulatory Support
Advanced Heart Failure/Transplant/Mechanical Circulatory Support
Minneapolis Heart Institute at Abbott Northwestern Hospital
Part of Allina Health
Minneapolis, MN
Innovation Summit 2014
September 26, 2014
2. 0
50
100
150
200
250
300
350
400
0
200
400
600
800
1000
1200
Heart Failure:
The Final Cardiovascular Disease
CORONARY DEATH
Deaths/100,000 population
HEART FAILURE
Prevalence/100,000 population
National Hospital Discharge Survey Data. Centers for Disease Control and Prevention
National Center for Health Statistics and National Heart, Lung, and Blood Institute
1980 1990 2000 1980 1990 2000
Improved survival in other CV diseases has led to expansion of the HF Population.
3. Survival(%)
100
80
60
40
20
0
0 6 12 18 24
Time (months)
J Heart Lung Transplant 2011;30:402–7
Advanced Heart Failure is
Cardiac Cancer
Stage IV Pancreatic Cancer
NYHA FC IV (Medical Therapy)
4. NOTE: This figure includes only the heart transplants that are
reported to the ISHLT Transplant Registry. As such, the
presented data may not mirror the changes in the number of
heart transplants performed worldwide
ISHLT
2011
J Heart Lung Transplant. 2011 Oct; 30 (10): 1071-1132
Heart Transplantation
Survival by Era
0
20
40
60
80
100
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Survival(%)
Years
1982-1992 (N = 25,138)
1993-2002 (N = 37,193)
2003-6/2010 (N = 24,021)
HALF-LIFE 1982-1992: 8.5 years; 1993-2002: 10.9 years; 2003-6/2010: NA
1982-1992 vs. 1993-2002: p < 0.0001
1982-1992 vs. 2003-6/2010: p <0.0001
1993-2002 vs. 2003-6/2010: p <0.0001
1-year 94%
3-year 90%
MHI at ANW
5. ~ 240 M
US Population ≥ 20 years old
6.24 M
HF = 2.6% of the population
3.12 M
Systolic HF = 50% of HF population
374,400
Stage C/D
NYHA IIIb-IV
93,600
Target VAD/Tx Population
Projected Advanced HF Therapy Population
1 US Census Bureau Statistics (2007)
2 Heart and Stroke Statistics, American Heart Association
3 Cardiovascular Round Table research and analysis, The Advisory Board company (2009)
280,800
Disqualifying
Comorbidities
-
There are currently
approximately
100,000 potential
candidates in the
United States.
Likely several
hundred in the
Allina System.
11. SHOCK TEAM
• Interventional Cardiologist
• Heart Failure Cardiologist
• Intensivist
• Cardiothoracic Surgeon
• Vascular Surgeon
• ICU Nurse
• Perfusionist
RAPID TRIAGE AND INITIATION
• Performed in cath lab
• Rapid assessment of
hemodynamics
• 20% of patients with ongoing
CPR at time of cannulation
13. • Bridge to Transplant*: Inserted for short to intermediate
term support in patients actively listed for transplant
• Destination Therapy*: Inserted with the intention of long
term support in patients who are not transplant candidates
• Bridge to Recovery: Inserted for short term support in a
condition that is anticipated to reverse (e.g., fulminant
myocarditis, EtOH cardiomyopathy, etc.)
• Bridge to Decision: Inserted for support when ultimate
therapy is not able to be determined at the time of
implantation
Defined Indications for Durable VADs
*only designations currently recognized by regulatory/payor community
~20% crossover in clinical trials (BTT!"DT)
14. • >18,000 implants
• Axial continuous-flow from LV to
ascending aorta
• Easy surgical implantation
• Smaller pre-peritoneal pocket
• Electrically powered
• Batteries & line power
• Silent, vibration-free operation
• Flow range: 3-10 L/min
• Designed for extended durability
with single moving part
HeartMate II® LVAD
15. Summary of HeartMate II ®
BTT Outcomes
Reference Study
Enrollment
period
n
Survival at 180
days
Miller, Pagani, Russell et al
NEJM 357:885-896, 2007
HM II Pivotal
Trial 3/05- 5/06 133 79%
Pagani, Miller, Russell et al
JACC 54:312-321, 2009
HM II Pivotal
Trial 3/05- 3/07 281 84%
Starling, Naka, Boyle et al
JACC 57:1890-1898, 2011
Post Approval
Study 4/08 – 8/08 169 91%
16. Summary of HeartMate II®
Destination Therapy Outcomes
Reference Study
Enrollment
period
n
One-Year
Survival
Two-Year
Survival
Slaughter, Rogers, Milano et al
NEJM 2009;361:2241-51.
HM II Pivotal
Trial 3/05- 5/07 134 68% 58%
Park, S et al
Circ Heart Failure 2012;5:241-8.
HM II Pivotal
Trial 5/07- 3/09 311 74% 64%
17. 0
50
100
150
200
250
300
Baseline 1 mo 3 mo 6 mo
Meters
30
166
244
285
JAAC 2009;54(4):312-21.
HeartMate II® BTT Trial
Improvement in 6-minute Walk and NYHA Class
0
10
20
30
40
50
60
70
80
90
100
Baseline 1 mo 3 mo 6 mo
%ofpatients
NYHA II
NYHA I
59%
83% 82%
0%
NYHA Functional Class6-minute Walk
18. 1. J Amer Coll Cardiol. 2011;57(19):1890-1898.
2. Stroke. 2006;37(2):562-571.
3. Two-Year Outcomes in the Destination Therapy Post-FDA-Approval Study with a Continuous Flow Left Ventricular Assist Device: A Prospective
Study Using the INTERMACS Registry. U.P. Jorde, S.S. Kushwaha, A.J. Tatooles, et al. Presented at the ISHLT annual meeting, April 25,
2013.
Device Related
Infection
Bleeding
Requiring
Surgery
Pump
Replacement
Isc Stroke Hem Stroke Hemolysis Thrombus
Trial Post-Approval Study
0.06
0.031
0.47
0.22 0.07
0.052
0.024
0.06
0.024
0.027
0.23
0.09
0.057
0.026
Events/patientyear
Note: 3x scale difference for Device infection and Bleeding requiring surgery compared to others
. . . Since the trial adverse event
occurrence continues to decline3
HeartMate II® BTT Trial
Adverse Event Rates are Falling with Clinical Experience
19. Heartware HVAD®
Centrifugal/Radial Flow LVAD
J Am Coll Cardiol. 2011;57(12):1375-1382
Circulation. 2012;125:3191-3200
Aorta
LV apex
• Centrifugal pump with hybrid magnetic/
hydrodynamic impeller suspension "
• 3,500 implants worldwide
• Approved for use in EU in January 2009
• FDA approved for BTT only in US
HeartWare® System
Small pump attaches
directly to the heart
Thin, flexible driveline
cable exits skin
A small controller &
batteries run the pump
CAUTION: Federal Law (USA) restricts this device to sale by or on the order of a physician. Refer to the “Instructions For Use” for
complete Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Instructions prior to using this device.
20. Months
0 6 12 18 24
PercentSurvival
0
10
20
30
40
50
60
70
80
90
100
68%
58%
55%
24%
8%
23%
25%
52%
NEJM 2001; 345:1435-43
NEJM 2009; 361:2241-2251
Continued Stepwise Improvement in
Survival in Clinical Trials
OMM Rose 2001
XVE DT Slaughter 2009
XVE DT Rose 2001
HMII DT Slaughter 2009
HMII BTT Pagani 2009
Heartware BTT 2013
88%
75%
~90% 1-year survival in
Bridge to Transplant Patients*
~70% 1-year survival in
Destination Therapy Patients*
22. Inlet
Cannula in
Left Atrium
Pump to the
Subclavian
Artery
Subcutaneous
pump implanted
like a pacemaker
CircuLite®: A Permanent, Partial Support
LVAD with Minimally Invasive Implantation
European Journal of Cardio-thoracic Surgery, 39 (2011) 693-698.
Can early, partial support
alter the natural history of
advanced HF?